ArticleLife (Basel, Switzerland)2022

The Allosteric Antagonist of the Sigma-2 Receptors-Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer's Disease: A Scoping Systematic Review.

Anum Rasheed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.